share_log

EF Hutton Assumes Lantern Pharma at Buy, Maintains Price Target of $11

Benzinga ·  May 25, 2023 05:26

EF Hutton analyst Michael King assumes Lantern Pharma (NASDAQ:LTRN) with a Buy rating and maintains Price Target of $11.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment